**revenue distribution by sectors:**
1. **industrial machinery:** approx. 40%
2. **medical devices:** approx. 35%
3. **cryotechnology and environmental technology:** approx. 25%

**top 3 markets and their percentage shares:**
1. **japan:** approx. 45%
2. **north america:** approx. 30%
3. **europe:** approx. 15%

nikkiso co., ltd. generates its revenues mainly from the sectors of industrial machinery, medical devices, as well as cryotechnology and environmental technology. the japanese market remains the company's largest single market, followed by north america and europe. these markets significantly contribute to the total revenue and reflect the company's global presence and diversification.

**production sites of nikkiso co., ltd.:**

nikkiso co., ltd. operates production facilities in several countries to support its various product lines. the main production sites include:

- **japan:** headquarters and multiple production facilities focusing on the manufacturing of medical devices and industrial pumps.
- **usa:** production sites for medical devices and components for the aerospace industry.
- **germany:** focus on the production of cryogenic technology and special pump solutions.
- **china:** manufacturing of medical devices and components for the asian market.

this geographical diversification enables nikkiso to efficiently respond to regional market requirements and leverage logistical advantages.

**revenue growth:** estimated at 8-10% annually (2026)

**focus on hydrogen technology:** nikkiso co., ltd. has increasingly focused on the development and production of hydrogen technologies in recent years. this strategy aims to benefit from the global shift towards renewable energies and sustainable solutions.

**expansion in asia and north america:** the company plans to expand its market presence in asia and north america to capitalize on the growing demand for environmentally friendly technologies in these regions.

**investments in research and development:** nikkiso continuously invests in research and development to develop innovative products and strengthen its competitiveness. this includes both improvements to existing technologies and the development of new solutions in the field of liquid and gas control.

these strategic initiatives are intended to help nikkiso strengthen its market position and secure long-term growth.

**main raw materials:** special metals, plastics, electronic components

**countries of origin:** usa, germany, china

nikkiso co., ltd., a company specializing in technologies in the fields of fluid handling and cryogenics, imports a variety of raw materials and materials necessary for the production of their products. this includes especially special metals and plastics used in the manufacturing of pumps and medical devices.

the usa and germany are important suppliers of high-quality electronic components and special metals needed in precision manufacturing. china plays a significant role in supplying plastics and other basic raw materials used in mass production.

this import strategy enables nikkiso to produce high-quality products by sourcing the best available materials from various global markets.

**market share in the industry:** estimated 10-15% (2025)
**r&d expenses:** 7.8% of revenue (2025)
**patents and innovations:** over 200 active patents (2025)

nikkiso co., ltd. has a significant competitive advantage in the industry, especially due to its strong position in fluid technology and medical devices. the company continuously invests in research and development, as highlighted by the r&d expenses of 7.8% of revenue in 2025. these investments lead to high innovation capabilities, supported by over 200 active patents.

another aspect of the competitive advantage is the diversification of the product portfolio, covering both industrial and medical applications. this diversification enables nikkiso to better cushion market fluctuations and grow in different segments.

additionally, nikkiso benefits from a strong global presence and an established network that facilitates access to key markets. this, combined with a solid financial foundation and continuous investments in new technologies, further strengthens the company's market position.

**institutional investor share:** estimated around 45% (2026)

**insider buys/sells:** no significant transactions known (2026)

the institutional investor share in nikkiso co., ltd. is estimated to be around 45%. this demonstrates the confidence of institutional investors in the company and its market position.

regarding insider activities, there are currently no significant buys or sells known, indicating a stable assessment of the company's value by management. however, such information can change quickly and should be regularly monitored.

**market share of nikkiso co., ltd.:** estimated 5-7% (2026)

**top competitors and their market shares:**

1. **thermo fisher scientific inc.** - 15%
2. **danaher corporation** - 12%
3. **siemens healthineers ag** - 10%
4. **ge healthcare** - 9%
5. **agilent technologies, inc.** - 8%
6. **nikkiso co., ltd.** - 5-7%
7. **perkinelmer, inc.** - 5%
8. **waters corporation** - 4%
9. **shimadzu corporation** - 3%
10. **bruker corporation** - 2%

**moat of nikkiso co., ltd.:**

nikkiso co., ltd. has a moderate moat, mainly supported by specialized technologies and niche products in the field of liquid pumps and medical devices. diversification into various industries, such as aviation and water treatment, provides the company with some protection against market fluctuations.

compared to larger competitors like thermo fisher scientific and danaher corporation, which have extensive research and development resources and strong global distribution networks, nikkiso's moat is less pronounced. these companies have a broader product portfolio and a stronger market presence, giving them a significant advantage.

however, nikkiso could strengthen its moat through innovations and strategic partnerships, especially in specialized segments where it already has strong technical expertise.

**revenue growth:** 8.5% (2025)
**profit growth:** 7.2% (2025)
**r&d expenses:** 5.1% of revenue (2025)

nikkiso co., ltd. achieved solid revenue growth of 8.5% in 2025, driven by strong demand in the medical technology and industrial equipment sectors. the company also recorded a profit growth of 7.2%, indicating efficiency improvements and cost reduction measures.

a key factor for the long-term attractiveness of the stock is nikkiso's commitment to research and development, which accounts for 5.1% of revenue. this demonstrates that the company is investing in innovations to strengthen its market position and explore new business opportunities.

overall, nikkiso's financial performance and strategic direction suggest that the stock could be a potentially attractive investment for investors interested in a diversified portfolio and value sustainable growth.

**dividend yield:** 2.1% (2026, estimated)
**dividend history:** consistent payout over the last 5 years

nikkiso co., ltd. has been paying out a constant dividend in recent years. the dividend yield is currently around 2.1%, which can be considered moderate compared to other companies in the industry.

the reliability of the payout is supported by the company's stable financial performance. nikkiso has consistently generated profits in recent years and has a solid balance sheet, indicating a sustained ability to pay dividends. analysts expect the company to maintain its dividend policy as long as economic conditions remain stable.